Key result
Cirsilineol inhibits Factor Xa, doubles aPTT, and suppresses thrombosis and platelet aggregation in mice.
Why the study?
The underlying mechanisms of the antithrombotic action of cirsilineol remained to be investigated.
Does cirsilineol inhibit Factor Xa activity, platelet aggregation, and thrombus formation compared to rivaroxaban and vehicle control in preclinical human cell and mouse models?
Does cirsilineol inhibit Factor Xa activity, platelet aggregation, and thrombus formation compared to rivaroxaban and vehicle control in preclinical human cell and mouse models?
Cirsilineol demonstrates dual Factor Xa inhibitory and antiplatelet properties in preclinical models, suggesting its potential as a novel pharmacological candidate for preventing arterial and venous thrombosis.
Answers are grounded in this paper and cite their sources.
Should not yet change practice; hypothesis-generating for dual Factor Xa and antiplatelet inhibition pending human trials.
, is lethal to many cancer cells and has antioxidant, anticancer, and antibacterial properties. Here, we investigated the underlying mechanisms of the antithrombotic action of CSL. We demonstrated that CSL has antithrombotic efficacy comparable to rivaroxaban, a direct blood coagulation factor Xa (FXa) inhibitor employed as a positive control, in inhibiting the enzymatic activity of FXa and the platelet aggregation induced by adenosine diphosphate (ADP) and U46619, a thromboxane A2 analog. The expression of P-selectin, the phosphorylation of myristoylated alanine-rich C kinase substrate by U46619 or ADP, and the activation of PAC-1 in platelets were inhibited by CSL. Nitric oxide production was increased by CSL in ADP- or U46619-treated human umbilical vein endothelial cells (HUVECs), although excessive endothelin-1 secretion was suppressed. CSL demonstrated strong anticoagulant and antithrombotic effects in a mouse model of arterial and pulmonary thrombosis. Our findings suggest that CSL is a potential pharmacological candidate for a novel class of anti-FXa and antiplatelet medications.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2023) studied Thrombosis and platelet aggregation (preclinical in vitro/in vivo models) (n=10). Cirsilineol (CSL) vs. Rivaroxaban (positive control) and DMSO/vehicle control was evaluated on Inhibition of Factor Xa (FXa) enzymatic activity, activated partial thromboplastin time (aPTT), agonist-induced platelet aggregation, and in vivo arterial/pulmonary thrombus formation (p=<0.05). Cirsilineol selectively inhibited Factor Xa, doubled aPTT at 7.23 μM in vitro and /kg ex vivo, and suppressed agonist-induced platelet aggregation and thrombosis in mice.
Synapse has enriched 10 related papers. Consider them for comparative context: